Abstract
Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
CNS & Neurological Disorders - Drug Targets
Title: Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
Volume: 10 Issue: 5
Author(s): Bradford D. Fischer
Affiliation:
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
Abstract: Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Export Options
About this article
Cite this article as:
D. Fischer Bradford, Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796235050
DOI https://dx.doi.org/10.2174/187152711796235050 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of On-Demand Caffeine Consumption on Treating Patients with Premature Ejaculation: A Double-Blind Randomized Clinical Trial
Current Pharmaceutical Biotechnology Meloxicam-loaded Phospholipid/solutol® HS15 Based Mixed Nanomicelles: Preparation, Characterization, and in vitro Antioxidant Activity
Pharmaceutical Nanotechnology Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection
CNS & Neurological Disorders - Drug Targets Editorial: Globalization and Child and Adolescent Mental Health
Adolescent Psychiatry The Novartis Compound Archive - From Concept to Reality
Combinatorial Chemistry & High Throughput Screening Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research PET and SPECT Radiotracers for Alzheimer's Disease
Current Medicinal Chemistry Extracorporeal Shock Wave Therapy for Calcific Tendonitis of the Rotator Cuff: A Review
Current Rheumatology Reviews Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery (Discontinued) Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry Why are Antidepressant Drugs Effective Smoking Cessation Aids?
Current Neuropharmacology Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Proteomics Studies in Oncology Towards Personalized Medicine in Public Health: Opportunities and Challenges for OMICS Research in Iran
Current Pharmacogenomics and Personalized Medicine